Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  R. Bellomo,et al.  Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2012, Critical Care.

[3]  B. Pitt,et al.  Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study , 2012, Circulation.

[4]  S. Kimmel,et al.  Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction , 2011, Circulation. Heart failure.

[5]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[6]  A. Young,et al.  Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. , 2010, The American journal of cardiology.

[7]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[8]  J. Townend,et al.  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. , 2009, Journal of the American College of Cardiology.

[9]  S. Navaneethan,et al.  Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[10]  J. Miyoshi,et al.  Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease , 2008, Nature Medicine.

[11]  F. Jaisser,et al.  Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling , 2008, Hypertension.

[12]  R. Blankstein,et al.  Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. , 2008, Heart failure clinics.

[13]  T. Fujita,et al.  Aldosterone and glomerular podocyte injury , 2008, Clinical and Experimental Nephrology.

[14]  A. Kshirsagar,et al.  Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  R. Bigazzi,et al.  Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. , 2006, Kidney international.

[16]  S. Solomon,et al.  Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. , 2006, Journal of the American Society of Nephrology : JASN.

[17]  D. Rizzoni,et al.  Renal Damage in Primary Aldosteronism: Results of the PAPY Study , 2006, Hypertension.

[18]  M. Novello,et al.  Long-term renal outcomes in patients with primary aldosteronism. , 2006, JAMA.

[19]  S. Solomon,et al.  Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study , 2004, Circulation.

[20]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[21]  S. Rajagopalan,et al.  Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[22]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[23]  S. Borzak,et al.  Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. , 2002, American heart journal.

[24]  A. Levin,et al.  Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[26]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[27]  A. Nishiyama,et al.  Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. , 2008, Journal of pharmacological sciences.